Is There Enough Evidence to Avoid Remdesivir Use in Patients with Severe Renal Impairment? A Review of the Pharmacological and Clinical Literature
Although patients with severe renal impairment (SRI) typically experience more critical symptoms once infected with novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2, this population has often been excluded from randomized controlled trials (RCT) for Coronavirus disease-2019 (COVID-...
Main Authors: | Suresh J. ANTONY, Emily L. HEYDEMANN, Katrina M. BROWN |
---|---|
Format: | Article |
Language: | Turkish |
Published: |
Galenos Yayinevi
2021-12-01
|
Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
Subjects: | |
Online Access: | http://mjima.org/abstract.php?id=231 |
Similar Items
-
Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study
by: Yan-Bo Huang, et al.
Published: (2024-02-01) -
Renal and liver injury following the treatment of COVID-19 by remdesivir
by: Mohsen Mohammad Rahimi, et al.
Published: (2021-04-01) -
Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment
by: Eunmi Yang, et al.
Published: (2024-01-01) -
Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study
by: Takumi Umemura, et al.
Published: (2022-11-01) -
Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia
by: Judit Cacho, et al.
Published: (2022-05-01)